drugset / Trial / NCT00325429
Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 52-week clinical study is designed as an open label, long-term study aimed to evaluate the safety of vildagliptin in patients with type 2 diabetes.
Timeline
- Start
- 2006-04
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vildagliptin | Other / unclassified | — | Oral |